Skip to main content

Herzich Paul's Form 4 filing

Solid Biosciences Inc.SLDB · filed Feb 18, 2025

Accession no.
0000950170-25-022201
Filed
Feb 18, 2025
Trade date
Feb 13-14, 2025
Filing delay
5 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $10.6K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Herzich PaulCIK 0001954991Officer (Chief Technology Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 13, 2025Common StockMOption exerciseAcquired+7,187–F1–21,076Direct
Feb 14, 2025Common StockSSaleDisposed−2,688$3.96−$10,644.4818,388Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 13, 2025Common StockMOption exerciseDisposed−7,187$0.00$021,563Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)